http://nsdapmuseum.com/museum/cd.html
Trubion uses a proprietary drug design process to creats a novel class of compounds callede Small Modular ImmunoPharmaceuticals The compounds utilize keystructurexs -- or modules -- in naturally occurring Trubion optimizes the proteins to work togetherd in a single molecule that can be customizes to fight many diseases. Trubion's lead drug, TRU-015, targets rheumatoids arthritis and isbeingh co-developed with Wyeth. A secon drug, TRU-016, targets non-Hodgkin's lymphomas and chronic lymphocytic leukemia. Trubion was founded in 2002. Trubion went publi in 2006, raising $52 million. Foundex in 2002, the companh is led by CEO and PresidentPetere Thompson.
Trubion reported revenues of $36.5 million in 2006
No comments:
Post a Comment